In vivo, Ex-4 has been demonstrated to inhibit prostate cancer cell growth by activating GLP-1R, reducing s-phase kinase-associated protein-2 (SKP2) gene expression, subsequently increasing p27Kip1 (p27) protein levels, and inducing tumor cell cycle arrest [67]
Novo Nordisk developed the first oral GLP-1 receptor agonist, semaglutide, marketed as Rybelsus and approved by the FDA in 2019 for Type 2 diabetes
The half-life of retatrutide is approximately six days, which is why weekly dosing works pharmacologically the drug stays active in your system through the week, maintaining receptor activation without requiring daily shots
Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice
You stuck with the program
During your consultation in Orlando, we'll create a realistic timeline